文献速递骨软组织肉瘤与黑色素瘤

LDH升高黑色素瘤患者一线靶向治疗或PD-1免疫检查点抑制的结局

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
PubMed 文献 · Eur J Cancer · 2021-03-15

这项多中心回顾性队列研究在25个黑色素瘤中心分析LDH升高患者一线靶向治疗(TT)或免疫检查点抑制(ICI)的无进展生存(PFS)和总生存(OS)。在173例BRAFV600突变患者中,双免疫联合较TT的12个月OS更高(83% vs 48%)。在314例一线ICI患者中,双免疫联合较抗PD-1单药的12个月OS更长(66% vs 54%)。

要点

  • BRAFV600突变且LDH升高者,双免疫联合较TT的12个月OS更高(83% vs 48%)。
  • 一线ICI人群中,双免疫联合较抗PD-1单药的12个月OS更长(66% vs 54%)。
  • TT组ORR为63%,双免疫联合为55%,抗PD-1单药为20%。

核心结论

  • 在BRAF突变且LDH升高的黑色素瘤患者中,双免疫联合(抗PD-1+抗CTLA-4)较一线TT似与更长的OS相关。
  • 在一线接受ICI的患者中,双免疫联合较抗PD-1单药似与更长的OS相关。

研究设计与样本

  • 多中心回顾性队列研究,在25个黑色素瘤中心开展,分析LDH升高患者的PFS和OS。
  • 采用逆概率治疗加权处理混杂因素。
  • BRAFV600突变患者173例;一线接受ICI患者314例。

主要发现

  • BRAFV600突变患者中,TT组12个月PFS为22%,双免疫联合组为52%(HR 0.6,95%CI 0.4-1.0,p=0.07),抗PD-1单药组为18%(HR 1.8,95%CI 1.2-2.8,p=0.003)。
  • BRAFV600突变患者中,TT组12个月OS为48%,双免疫联合组为83%(HR 0.5,95%CI 0.3-1.0,p=0.03),抗PD-1单药组为50%(HR 1.2,95%CI 0.8-2.0,p=0.37)。
  • TT组ORR为63%,双免疫联合组为55%,抗PD-1单药组为20%。
  • 一线ICI患者中,抗PD-1组12个月PFS为33%,双免疫联合组为38%(HR 0.8,95%CI 0.6-1.0,p=0.07);12个月OS分别为54%和66%(HR 0.7,95%CI 0.5-1.0,p=0.03)。
  • 一线ICI患者中,抗PD-1单药组ORR为30%,双免疫联合组为43%。

关键数值与推荐

  • BRAFV600突变且LDH升高患者:双免疫联合组12个月OS 83%,TT组48%(HR 0.5,95%CI 0.3-1.0,p=0.03)。
  • BRAFV600突变且LDH升高患者:双免疫联合组12个月PFS 52%,TT组22%(HR 0.6,95%CI 0.4-1.0,p=0.07)。
  • 一线ICI患者:双免疫联合组12个月OS 66%,抗PD-1单药组54%(HR 0.7,95%CI 0.5-1.0,p=0.03)。

临床怎么用

  • 对BRAF突变且LDH升高的黑色素瘤患者,一线选择双免疫联合可能较TT或抗PD-1单药带来更长OS。
  • LDH升高患者一线ICI时,双免疫联合可能较抗PD-1单药带来更长OS。
  • 治疗决策需结合回顾性证据与患者个体情况综合判断。

局限性

  • 回顾性队列研究,存在混杂和选择偏倚可能。
  • 部分比较的P值未达统计学显著性(如PFS p=0.07)。
  • BRAFV600突变分析样本量为173例,一线ICI分析样本量为314例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elevated lactate dehydrogenase (LDH) is a known predictive and prognostic factor for a poor outcome in patients with metastatic melanoma. It is unclear whether first-line targeted therapy (TT) or immune checkpoint inhibition (ICI) is more beneficial in melanoma patients with elevated LDH because prospective studies in this area are lacking. METHODS: This multicentre retrospective cohort study was conducted at 25 melanoma centres worldwide to analyse progression-free survival (PFS) and overall survival (OS) among melanoma patients with elevated LDH. The role of confounders was addressed by using inverse probability of treatment weighting. RESULTS: Among 173 BRAFV600-mutant patients, PFS at 12 months in the TT group was 22% compared with 52% in the combined anti-PD-1 and anti-CTLA-4 group (HR 0.6, 95% CI 0.4-1.0, p = 0.07) and 18% in the anti-PD-1 monotherapy group (HR 1.8, 95% CI 1.2-2.8, p = 0.003). Twelve months' OS was 48% in the TT group compared with 83% in the combined anti-PD-1 and anti-CTLA-4 group (HR 0.5, 95% CI 0.3-1.0, p = 0.03) and 50% in the anti-PD-1 monotherapy group (HR 1.2, 95% CI 0.8-2.0, p = 0.37). The ORR in the TT group was 63%, compared with 55% and 20% in the combined anti-PD-1 and anti-CTLA-4 and anti-PD-1 monotherapy group, respectively. Among 314 patients receiving ICI first-line, PFS at 12 months was 33% in the anti-PD-1 group versus 38% in the combined anti-PD-1 and anti-CTLA-4 group (HR 0.8, 95% CI 0.6-1.0; p = 0.07). OS at 12 months was 54% in the anti-PD-1 group versus 66% in the combined ICI group (HR 0.7, 95% CI 0.5-1.0; p = 0.03). The ORR was 30% in the anti-PD-1 monotherapy group and 43% in the combined anti-PD-1 and anti-CTLA-4 group. Results from multivariate analysis confirmed the absence of qualitative confounding. CONCLUSIONS: Among BRAF-mutant patients with elevated LDH, combined anti-PD-1 and anti-CTLA-4 blockade seems to be associated with prolonged OS compared with first-line TT. Among patients receiving ICI as a first-line treatment, OS appears to be longer for the combination of anti-PD-1 and anti-CTLA-4 than for anti-PD-1 alone.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Knispel S, Gassenmaier M, Menzies AM, et al. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. Eur J Cancer. 2021. PMID: 33735811. doi:10.1016/j.ejca.2021.01.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。